T-activation® Technology

Fast, reliable, inexpensive and specific stimulation of a broad spectrum of clinically-relevant immune effector cells (CD4+, CD8+, NK and NKT-like cells) with Lophius’ T-activated® proteins.   

Fields of application:    

  • Better T cell-based diagnostic solutions for viral infections like CMV, EBV, BKV,...
  • Enhanced vaccine efficacy through improved immunogenicity of proteins
  • Improved immunomonitoring due to higher assay sensitivity

    T-activation® Technology:
    Enhanced immunogenicity of proteins

    In contrast to peptides and unmodified proteins, T-activated® proteins (formulated with Lophius' patented T-activation® buffer) are processed and cross-presented via the exogenous (MHC-II) and endogenous (MHC-I) pathways by functional antigen-presenting cells (APC), thus mimicking a natural infection (Figure 1).

    In addition, T-activated® proteins allow a more efficient and HLA antigen-independent stimulation of a broad spectrum of clinically-relevant subpopulations of antigen-reactive effector cells (CD4+ and CD8+ T cells, NK and NKT-like cells), as outlined in Figure 2.

     

     

    Figure 1 – Cross-presentation of T-activated® proteins by APC via the exogeneous (MHCII) and endogeneous (MHCI) pathways followed by IFN-γ secretion of stimulated T cells after TCR : MHC interaction.
    Figure 2 – Network of antigen-reactive effector cells stimulated via T-activated® proteins.

    Advantages of T-activated® proteins:

    • Enhanced immune-stimulatory capacity and immunogenicity of proteins
    • Cross-presentation by APC along MHC-I and MHC-II pathways
    • Closely mimicking the natural uptake, processing and presentation of antigens
    • Stimulation of a broad spectrum of clinically-relevant effector cells (Th, CTL, NK, NKT-like cells)
    • HLA antigen-independent stimulation
    • Applicable for multiple immunological assays and read-out systems, including ELISpot, FACS and ELISA

     

    Fields of application:

    • T cell-based diagnostic solutions for viral infections like CMV, EBV, BKV …
    • Transplantation medicine, autoimmune diseases, cancer …
    • Improved immunogenicity / enhanced performance of vaccines
    • Enhanced assay sensitivity, e.g. for monitoring immune responses against tumor-associated antigens


    References:

    • Barabas S et al. (2008). Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein. PLoS Pathog. 4:e1000198. (Read more)
    • Barabas S et al. (2017). An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity. BMC Immunol. 18:14. (Read more)
    • Banas B et al. (2017). Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 18:15. (Read more)
    • Reuschel E et al. (2017). Functional impairment of CMV-reactive cellular immunity during pregnancy. J. Med. Virol. 89:324-331. (Read more)

     

    International patents:

    • WO/2010/115984  “METHOD FOR POLYPEPTIDE TRANSFER INTO CELLS”
    • WO/2003/080792  “USE OF UREA-ADJUVATED POLYPEPTIDES FOR DIAGNOSIS, PROPHYLAXIS AND TREATMENT”
    • WO/2003/046212  “METHOD FOR IDENTIFYING TARGET EPITOPES OF THE T CELL MEDIATED IMMUNE RESPONSE AND FOR ASSAYING EPITOPE-SPECIFIC T CELLS”

     

     


    This function requires IE9 or higher.
    You can update your browser under:
    http://windows.microsoft.com/de-DE/internet-explorer/download-ie